RxDoctor Payments Data

Ari Moskowitz, MD

Critical Care Medicine · Weymouth, MANPI 1083908867

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 2 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Masimo Corporation accounts for 62.3% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for critical care medicine clinicians in MA, where the typical reported total is $228.

$73in general payments, 2019–2025

Across 2 payments — averaging $36.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Masimo Corporation$45
  • Biomerieux Inc$27
$299,882in research payments, 2019–2025

Across 26 payments — averaging $11,534 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$205K
  • Regeneron$94K

What the payments were for

  • Food & beverage$73100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Masimo Corporation1$45
Biomerieux Inc1$27

How this compares

$73 in reported general payments places this provider in the 25th percentile of 158 critical care medicine providers in Massachusetts.

See all critical care medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$48,182
Medicare patients
79
Services billed
312

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other critical care medicine in Weymouth

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →